MedWorm: Anal Cancer

The psychological impact of anal cancer screening on HIV‐infected men

Psycho-Oncology — Tue, 31 Jan 2012 05:00:00 +0100

ConclusionsAnal cancer specific worry increases throughout the screening process. Clear communication prior to procedures about the procedure itself, potential adverse events, the recovery process and non‐technical explanations of results should be implemented in anal screening programmes.Copyright © 2012 John Wiley & Sons, Ltd. (Source: Psycho-Oncology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Familial SLE: sustained drug-free remission in a mother successfully treated for anal cancer, but development of SLE in a 16-year old daughter.

Lupus — Wed, 11 Jan 2012 05:00:00 +0100

Authors: Catania G, Rossi E, Marmont A Abstract The immunopathogenesis of systemic lupus erythematosus has been thoroughly investigated recently, and genome-wide association studies have identified genes statistically associated with lupus. However, the progression to overt disease is dependent on the activation of environmental factors ('triggers'), among which oestrogen stimulation is prominent. Here we report the case of a mother with long-standing SLE entering into long term drug-free remission following intensive, menopause-inducing chemoradiotherapy for cancer, and the opposite case of her daughter, who developed SLE following the initiation of her menstrual cycle. PMID: 22236910 [PubMed - as supplied by publisher] (Source: Lupus)

Intraosseous Fibrosarcoma of Maxilla in an HIV Patient.

Archives of Iranian Medicine — Sun, 01 Jan 2012 05:00:00 +0100

Authors: Kotrashetti VS, Kale AD, Hallikeremath SR, Mane DR, V Angadi P, Bhatt P Abstract Fibrosarcoma is a malignant mesenchymal neoplasm of fibroblasts that rarely affects the oral cavity and can cause local recurrences or metastasis. Fibrosarcomas account for 15% of all soft tissue sarcomas, which represent only 1% of all malignant tumors of the head and neck region. The clinical behavior of the fibrosarcoma is characterized by a high local recurrence rate, and low incidence of loco regional lymph node and/or distant hematogenous metastasis. The etiology for fibrosarcoma has no definite cause but is thought to occur from preexisting lesions or in previously irradiated areas of bone lesions. Immunosuppression associated with HIV infection and acquired immune deficiency syndrome (...

Review of Screening Guidelines for Non-AIDS-Defining Malignancies: Evolving Issues in the Era of Highly Active Antiretroviral Therapy.

AIDS Reviews — Sun, 01 Jan 2012 05:00:00 +0100

Authors: Tyerman Z, Aboulafia DM Abstract HIV-associated morbidity and mortality have declined dramatically in the era of HAART. Through direct and indirect benefits of HAART, people with HIV/AIDS are living longer, developing less AIDS-defining cancers and more cancers commonly seen in the seronegative population. Herein, we review cancer screening strategies for people living with HIV and compare and contrast them with those of the general population. The most noticeable differences occur in anal and cervical cancer screening. Although anal cancer is uncommon in the general population, it is more prevalent in men who have sex with men and people at high risk for human papillomavirus infection, especially those infected with HIV. To address this, we recommend that a digital rectal...

11. MR imaging of anal cancer: a pictorial review.

Cancer Imaging — Mon, 26 Dec 2011 17:24:03 +0100

Authors: Wan M, Meacock L, Summers J, Elliott J, Houghton S Abstract Anal cancer is uncommon but is believed to be rising in incidence. The recently published European Society of Medical Oncology clinical practice guideline has endorsed magnetic resonance (MR) imaging as the modality of choice in the assessment of locoregional disease at primary presentation and as a useful tool for evaluation of treatment response. Surgery or chemoradiotherapy may be the optimal primary treatment modality depending on tumour stage. Local disease staging is therefore crucial for treatment decision. Accurate delineation of the disease in relation to the rest of the perineal anatomy is of paramount importance, not only in staging but also in surgical and radiotherapy planning. This provides a challen...

Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males - Advisory Committee on Immunization Practices (ACIP), 2011.

MMWR Morb Mortal Wkl... — Fri, 23 Dec 2011 05:00:00 +0100

Authors: Abstract On October 25, 2011, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of quadrivalent human papillomavirus (HPV) vaccine (HPV4; Gardasil, Merck & Co. Inc.) in males aged 11 or 12 years. ACIP also recommended vaccination with HPV4 for males aged 13 through 21 years who have not been vaccinated previously or who have not completed the 3-dose series; males aged 22 through 26 years may be vaccinated. These recommendations replace the October 2009 ACIP guidance that HPV4 may be given to males aged 9 through 26 years. For these recommendations, ACIP considered information on vaccine efficacy (including data available since October 2009, on prevention of grade 2 or 3 anal intraepithelial neoplasia [AIN2/3], a precursor of anal cancer)...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Fluorescence diagnostics as a guide for demarcation and biopsy of suspected anal cancer

International Journal of Dermatology — Thu, 22 Dec 2011 05:56:04 +0100

Conclusions FD is a non‐invasive technique which can be used in the perianal region in order to delineate pathologic processes which may reduce the number of surgical interventions. (Source: International Journal of Dermatology)

[Should the treatment of anal carcinoma be adapted in the elderly? A retrospective analysis of acute toxicities in a French centre and a review of the literature.]

Cancer Radiotherapie — Wed, 21 Dec 2011 05:00:00 +0100

CONCLUSIONS: Concomitant radiochemotherapy followed by brachytherapy showed an acceptable toxicity profile, and seems to be adapted in selected elderly patients. It could be recommended as reference treatment in elderly patients with a good physiological status. PMID: 22197192 [PubMed - as supplied by publisher] (Source: Cancer Radiotherapie)

Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression

Annals of Oncology — Tue, 20 Dec 2011 05:00:00 +0100

Conclusions: The management of anal cancer with CRT achieves similar outcomes as the general population. CRT is associated with significant prolonged CD4 suppression that may contribute to late deaths of patients in remission. (Source: Annals of Oncology)

Diagnosis, Treatment, and Prevention of Anal Cancer

Current Infectious Disease Reports — Tue, 29 Nov 2011 22:20:03 +0100

Abstract Rare in the general population, anal cancer has reached epidemic proportions among HIV-infected men who have sex with men (MSM). These cancers are human papillomavirus (HPV)-associated, usually HPV type16, and are analogous to cervical cancer. At present, the rates of anal cancer in this group are 10-fold higher than that of cervical cancer occurring in women in the general population. Although there are no national guidelines for screening for anal intraepithelial dysplasia (AIN), many large HIV clinics are now performing anal cytologic screening in their at-risk patients. This paper outlines the current approach to screening for AIN and its management. Content Type Journal ArticleCategory HIV/AIDS (RD MacArthur, Section Editor)Pages 1-6DOI 10.1007/s11908-011...

[Editorial] Tapping our immune potential to realise the ultimate goal

The Lancet Oncology — Mon, 28 Nov 2011 02:01:45 +0100

Last month, the immune surveillance theory—which proposes that the immune system continuously identifies, and removes, malignant cells as they arise—was lent further weight by an article in JAMA, which showed that recipients of organ transplants have an increased risk for an array of cancers—both related and unrelated to infection—compared with the general population. An increase in infection-related cancers (eg, non-Hodgkin lymphoma, gastric cancer, anal cancer, and Kaposi's sarcoma) might be anticipated, given that use of immunosuppression to reduce the risk of transplant rejection is likely to result in poor immune control of known oncogenic pathogens. (Source: The Lancet Oncology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

High prevalence of HPV in non-cervical sites of women with abnormal cervical cytology

BMC Cancer — Wed, 02 Nov 2011 04:00:00 +0100

Conclusions: Women with abnormal smears have widespread infection with high-risk HPV at the cervical, anal and oro-pharyngeal mucosal sites and may represent a higher risk population for HPV disease in the future. (Source: BMC Cancer)

Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients [Original Contribution]

JAMA — Tue, 01 Nov 2011 04:00:00 +0100

Conclusion Compared with the general population, recipients of a kidney, liver, heart, or lung transplant have an increased risk for diverse infection-related and unrelated cancers. (Source: JAMA)

Falling Between the Cracks: Anal Dysplasia and Anal Cancer in HIV Care

Journal of the Association of Nurses in AIDS Care — Tue, 01 Nov 2011 04:00:00 +0100

As much as I would have liked to have kept my cancer private,I now realize that I have a certain responsibilityto those who are fighting their own fightsand may be able to benefit from learning about mine.— Farrah Fawcett on her cancer (, ¶ 14)I know that everyone will die eventually,but I do not want to die of this disease.— Farrah Fawcett on her cancer (, ¶ 22) (Source: Journal of the Association of Nurses in AIDS Care)

A Conversation With High-Resolution Anoscopists: Perspectives From Nurse Practitioner Experts

Journal of the Association of Nurses in AIDS Care — Tue, 01 Nov 2011 04:00:00 +0100

Recent data suggest that persons living with HIV (PLWH) are at significantly greater risk of developing anal cancer than the general population (). The development of anal cancer is associated with infection with human papilloma virus (HPV) (). HPV causes dysregulation at the cellular level in the anal canal leading to dysplastic changes, referred to as anal intraepithelial neoplasia (AIN), or anal dysplasia (). It is hypothesized that identification of anal dysplasia and treatment of dysplastic lesions can reduce the occurrence of anal cancer; however, definitive data are still pending. (Source: Journal of the Association of Nurses in AIDS Care)

The Need for Anal Dysplasia Screening and Treatment Programs for HIV-Infected Men Who Have Sex With Men: A Review of the Literature

Journal of the Association of Nurses in AIDS Care — Tue, 01 Nov 2011 04:00:00 +0100

Anal cancer rates, which were higher for men who have sex with men (MSM) compared to the general population before HIV, increased dramatically after the HIV epidemic began and continue to increase in HIV-infected MSM despite the advent of antiretroviral therapy and associated immune reconstitution. Because of the similarity to cervical cancer and an established link to human papillomavirus infection, many experts have called for widespread implementation of anal cytological screening and treatment programs, especially for HIV-infected MSM. However, other experts argue that it is too early for widespread implementation of such programs for reasons including lack of clear evidence that anal dysplasia is a precursor to anal cancer, or that detecting and treating anal dysplasia reduces the ris...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

The Importance of HIV Status and Gender When Designing Prevention Strategies for Anal Cancer

Journal of the Association of Nurses in AIDS Care — Tue, 01 Nov 2011 04:00:00 +0100

Our objective is to review and summarize relevant aspects of the literature regarding human papillomavirus (HPV), the most common sexually transmitted infection in the United States, and to compare how the trajectory of HPV may differ in persons who are and who are not co-infected with HIV. This comparison is particularly important because the literature on HPV has been largely based on individuals who are not co-infected with HIV. Also, HPV findings may differ in HIV-uninfected individuals versus HIV-infected individuals. In addition, many reviews ignore gender differences, although in HIV-uninfected individuals, anal cancers are up to 4 times more prevalent in women than men. Clinical decision making may be problematic if such critical factors as HIV status and gender are neglected. Ther...

Elements of an Anal Dysplasia Screening Program

Journal of the Association of Nurses in AIDS Care — Tue, 01 Nov 2011 04:00:00 +0100

This article discusses the procedures for anal cancer screening including cytology, digital anal rectal examinations, high-resolution anoscopy, and biopsy. (Source: Journal of the Association of Nurses in AIDS Care)

Infusing Swanson’s Theory of Caring into an Advanced Practice Nursing Model for an Infectious Diseases Anal Dysplasia Clinic

Journal of the Association of Nurses in AIDS Care — Tue, 01 Nov 2011 04:00:00 +0100

This article describes the application of a theory of caring to create an advanced practice nursing model of care for HIV-infected men and women in infectious diseases anal dysplasia clinics. (Source: Journal of the Association of Nurses in AIDS Care)

Vaccine Fights Anal Cancer

Medical Headlines From Ivanhoe.com — Fri, 28 Oct 2011 05:00:00 +0100

(Ivanhoe Newswire) – The rate of anal cancer is increasing, particularly among men who have sex with men. (Source: Medical Headlines From Ivanhoe.com)

Clinical Trial Shows First Evidence That Anal Cancer Is Preventable

Health News from Medical News Today — Thu, 27 Oct 2011 08:00:00 +0100

A large, international clinical trial led by doctors at the University of California, San Francisco indicates that a vaccine to prevent anal cancer is safe and effective, according to a study reported in the October 27, 2011 issue of New England Journal of Medicine. Though anal cancer is less common than other forms of the disease in the United States, the number of cases has increased in recent years, and is particularly common among men who have sex with men and HIV-infected individuals... (Source: Health News from Medical News Today)

MedWorm Sponsor Message: Find the best January Sales in the UK.

HPV Vaccine Might Help Prevent Anal Cancers: Study

MedicineNet Cancer General — Thu, 27 Oct 2011 07:00:00 +0100

Title: HPV Vaccine Might Help Prevent Anal Cancers: StudyCategory: Health NewsCreated: 10/26/2011 6:06:00 PMLast Editorial Review: 10/27/2011 (Source: MedicineNet Cancer General)

Substudy finds HPV vaccine protects against anal intraepithelial neoplasia

NeLM - News — Thu, 27 Oct 2011 04:00:00 +0100

Source: N Engl J Med Area: News According to a substudy of a large double-blind study evaluating the quadrivalent human papillomavirus (HPV) vaccine in young men, use of this vaccine in men who have sex with men reduces the rate of anal intraepithelial neoplasia, and may therefore help to reduce the risk of anal cancer. The authors note that the incidence of anal cancer is rare but increasing, and it is particularly common among certain groups, including men who have sex with men. It has a causal relationship with HPV infection; the proportion of anal cancers associated with HPV type 16 or 18 is at least as high as that seen with cervical cancers. Anal cancer is preceded by high-grade anal intraepithelial neoplasia (grade 2 or 3) and the prevention or treatment of t...

Clinical trial shows first evidence that anal cancer is preventable

ScienceDaily Headlines — Wed, 26 Oct 2011 21:53:53 +0100

A large, international clinical trial indicates that a vaccine to prevent anal cancer is safe and effective, according to a new study. (Source: ScienceDaily Headlines)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

HPV Vaccine Cuts Risk of Anal Pre-Cancers (CME/CE)

MedPage Today Geriatrics — Wed, 26 Oct 2011 21:12:46 +0100

(MedPage Today) -- Among men who have sex with men, the vaccine against human papillomavirus (HPV) reduces the risk of the precursors of anal cancer, researchers reported. (Source: MedPage Today Geriatrics)

HPV Vaccine Might Help Prevent Anal Cancers

MedlinePlus Health News — Wed, 26 Oct 2011 21:00:00 +0100

Research in gay and bisexual men suggests it reduces infections, lesions Source: HealthDay Related MedlinePlus Pages: Anal Cancer, Gay, Lesbian and Transgender Health, HPV (Source: MedlinePlus Health News)

HPV vaccine for boys may be hard sell: Why?

Health News: CBSNews.com — Wed, 26 Oct 2011 13:44:34 +0100

Government panel calls for boys to get vaccinated against virus linked to genital warts and anal cancer (Source: Health News: CBSNews.com)

Clinical trial shows first evidence that anal cancer is preventable

EurekAlert! - Medicine and Health — Wed, 26 Oct 2011 04:00:00 +0100

(University of California - San Francisco) A large, international clinical trial led by doctors at the University of California, San Francisco indicates that a vaccine to prevent anal cancer is safe and effective, according to a study reported in the Oct. 27, 2011 issue of New England Journal of Medicine. (Source: EurekAlert! - Medicine and Health)

HPV Vaccine Might Help Prevent Anal Cancers: Study

The Doctors Lounge - Infections — Wed, 26 Oct 2011 04:00:00 +0100

Research in gay and bisexual men suggests it reduces infections, lesions (Source: The Doctors Lounge - Infections)

MedWorm Sponsor Message: Find the best January Sales in the UK.

ACIP votes for expanded use of HPV vaccine in boys, young men

Modern Medicine — Wed, 26 Oct 2011 04:00:00 +0100

The Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) voted to recommend that boys aged 11 to 12 years be vaccinated routinely with human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant (Gardasil, Merck) to help prevent anal cancer caused by human papillomavirus (HPV) types 16 and 18, anal dysplasias and precancerous lesions caused by HPV types 6, 11, 16, and 18, and genital warts caused by HPV types 6 and 11. (Source: Modern Medicine)

Routine HPV vaccine recommended for boys

Los Angeles Times - Science — Wed, 26 Oct 2011 02:48:00 +0100

The panel that advises the CDC on vaccines recommends that the shot be given to boys ages 11 and 12 in addition to girls, noting that the virus is linked to many other cancers besides cervical.A vaccine that protects against the sexually transmitted human papillomavirus should be routinely given to boys ages 11 and 12 to prevent anal cancer, a government advisory committee has decided. (Source: Los Angeles Times - Science)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

HPV Vaccine For 11-12 Year Old Boys Approved By CDC Advisory Committee, USA

Health News from Medical News Today — Wed, 26 Oct 2011 02:00:00 +0100

The CDC's ACIP (Advisory Committee on Immunization Practices) has recommended the routine administration of 3-doses of HPV4 vaccine to protect against HPV (Human Papilloma Virus). The Committee said the vaccine will not only protect males from some HPV-related conditions, such as genital warts and oral, penile and anal cancers, but will also indirectly protect females by reducing HPV infection risk, a common cause of cervical cancer. A significant proportion of cervical cancers result from vaginal sex with HPV infected males... (Source: Health News from Medical News Today)

HPV Vaccine Might Help Prevent Anal Cancers: Study

Cancercompass News: Other Cancer — Wed, 26 Oct 2011 00:00:00 +0100

Research in gay and bisexual men suggests it reduces infections, lesions (Source: Cancercompass News: Other Cancer)

IDSA: HIV Patients Face Early Anal Cancer Risk (CME/CE)

MedPage Today State Required CME — Tue, 25 Oct 2011 19:12:57 +0100

BOSTON (MedPage Today) -- Anal intraepithelial neoplasia seems to develop during the first year of HIV infection, according to the results of a cross-sectional study. (Source: MedPage Today State Required CME)

U.S. advisers recommend Gardasil HPV shots for boys

Reuters: Health — Tue, 25 Oct 2011 15:27:58 +0100

CHICAGO (Reuters) - U.S. vaccine advisers on Tuesday voted to recommend that boys should be routinely vaccinated with Merck & Co's Gardasil vaccine to protect them from human papillomavirus or HPV infections, which cause genital warts and oral, penile and anal cancers in boys and men, and cervical cancers in women. (Source: Reuters: Health)

The HPV vaccine, recommended for girls, prevents anal cancer when given to boys and young men, a study indicates.

OrlandoSentinel: Medical Research — Mon, 24 Oct 2011 14:14:26 +0100

(Source: OrlandoSentinel: Medical Research)

MedWorm Sponsor Message: Find the best January Sales in the UK.

HIV and cancer in Africa: mutual collaboration between HIV and cancer programs may provide timely research and public health data

Infectious Agents and Cancer — Mon, 17 Oct 2011 04:00:00 +0100

The eruption of Kaposi sarcoma (KS) and aggressive non-Hodgkin lymphoma (NHL) in young homosexual men in 1981 in the West heralded the onset of the human immunodeficiency virus (HIV) infection epidemic, which remains one of the biggest challenges to global public health and science ever. Because KS and NHL were increased >10,000 and 50-600 times, respectively, with HIV, they were designated AIDS defining cancers (ADC). Cervical cancer (CC), increased 5-10 times, was also designated as an ADC. A few other cancers are elevated with HIV, including Hodgkin lymphoma (10 times), anal cancer (15-30 times), and lung cancer (4 times) are designated as non-AIDS defining cancers (NADCs). Since 1996 when combination antiretroviral therapy (cART) became widely available in the West, dramatic decreases ...

Colon, Rectal, and Anal Cancers

Cancer Network — Thu, 13 Oct 2011 12:00:00 +0100

Despite the existence of excellent screening and preventive strategies, colorectal carcinoma (CRC) remains a major public health problem in Western countries. ACS estimated that in 2010, 142,570 people will be diagnosed with CRC, and 51,370 will die of the disease. (Source: Cancer Network)

Node-negative T1–T2 anal cancer: Radiotherapy alone or concomitant chemoradiotherapy?

Radiotherapy and Oncology — Thu, 13 Oct 2011 04:00:00 +0100

Conclusions: In the management of node negative T1–T2 anal cancer, LRC and CSS tend to be superior in patients treated by combined CRT, even though the difference was not significant. Randomized studies are warranted to assess definitively the role of combined treatment in early-stage anal carcinoma. (Source: Radiotherapy and Oncology)

Node-negative T1-T2 anal cancer: Radiotherapy alone or concomitant chemoradiotherapy?

Mon, 10 Oct 2011 04:00:00 +0100

CONCLUSIONS: In the management of node negative T1-T2 anal cancer, LRC and CSS tend to be superior in patients treated by combined CRT, even though the difference was not significant. Randomized studies are warranted to assess definitively the role of combined treatment in early-stage anal carcinoma. PMID: 21993403 [PubMed - as supplied by publisher] (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

BMC Cancer — Fri, 07 Oct 2011 04:00:00 +0100

Conclusions: Thrombocytopenia, and to a lesser extent neutropenia, was the DLT of weekly PR-104. The MTD was 675 mg/m2/week. PR-104 given weekly may be a suitable protocol for further clinical evaluation as a short course of treatment with fractionated radiotherapy or haematopoietic stem cell support, as its duration of dosing is restricted by delayed-onset and protracted thrombocytopenia. (Source: BMC Cancer)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Intensity-Modulated Radiotherapy for Squamous Cell Carcinoma of the Anal Canal: Efficacy of a Low Daily Dose to Clinically Negative Regions

Radiation Oncology — Thu, 06 Oct 2011 04:00:00 +0100

Conclusions: Our data support using doses between 1.50 and 1.80 Gy/day to clinically uninvolved regions. (Source: Radiation Oncology)

HPV Vaccine in Men: A Good Thing But Worth the Cost?HPV Vaccine in Men: A Good Thing But Worth the Cost?

Medscape PublicHealth Headlines — Wed, 05 Oct 2011 16:00:00 +0100

Sandra Fryhofer, MD, describes the latest evidence on the benefits of the human papillomavirus vaccine in men, especially in preventing anal cancers. Medscape Internal Medicine (Source: Medscape PublicHealth Headlines)

HPV-Related Anal Cancer Risk High in Lupus (CME/CE)

MedPage Today Dermatology — Fri, 30 Sep 2011 20:46:00 +0100

(MedPage Today) -- Patients with systemic lupus erythematosus are at elevated risk for virus-associated malignancies, data from a Danish registry showed. (Source: MedPage Today Dermatology)

High incidence of potentially virus‐induced malignancies in systemic lupus erythematosus: A long‐term followup study in a Danish cohort

Arthritis and Rheumatism — Fri, 30 Sep 2011 00:22:24 +0100

ConclusionThe patients in this SLE cohort experienced an increased risk of HPV‐associated tumors and other potentially virus‐induced cancers during long‐term followup. Our findings call for clinical alertness to oncogenic virus infections in SLE patients. (Source: Arthritis and Rheumatism)

Anal cancer treatment may lead to colostomy

MedWire News - Gastroenterology — Thu, 29 Sep 2011 08:29:02 +0100

The need for colostomy in patients who undergo radiotherapy for anal cancer appears to be related, in a third of cases, to their treatment, study findings suggest. (Source: MedWire News - Gastroenterology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Metachronous Anal Canal and Prostate Cancers with Simultaneous Definitive Therapy: A Case Report and Review of the Literature

Computational Intelligence and Neuroscience — Thu, 15 Sep 2011 15:32:33 +0100

Anal canal cancer is rare, accounting for only 1.3% of all gastrointestinal tract malignancies. Prostate cancer incidence is much higher and accounts for 27.6% of all malignancies in men. Treatment guidelines for anal cancer involve radiotherapy to the primary site and draining lymphatics while treatment for prostate cancer can also include pelvic radiotherapy. The literature is silent on the optimum course of action when these two malignancies are found synchronously or metachronously. Herein, we report a case of a patient diagnosed with intermediate risk prostate cancer who, prior to definitive therapy for this first malignancy, was also diagnosed with anal canal cancer. We conclude that a simultaneous approach with radiation therapy and chemotherapy with subsequent boost to the prostate...

Cause-Specific Colostomy Rates After Radiotherapy for Anal Cancer: A Danish Multicentre Cohort Study [Gastrointestinal Cancer]

Journal of Clinical Oncology — Thu, 08 Sep 2011 04:00:00 +0100

Conclusion After curative-intent radiotherapy or chemoradiotherapy, one third of patients had a colostomy, of which one third were related to therapy. Large tumor size was associated with a higher risk of tumor-related colostomy, whereas history of prior excision was associated with an increased incidence of therapy-related colostomy. (Source: Journal of Clinical Oncology)

Malignancies of the anal canal

Techniques in Coloproctology — Fri, 02 Sep 2011 05:48:37 +0100

Conclusions It seems that in our center the frequency and prevalence of anal adenocarcinoma is increased compared to the results from international data. More studies involving larger series of patients are required in order to shed further light in the true incidence of anal cancer and it subtypes in Hellenic population. Content Type Journal ArticlePages 1-3DOI 10.1007/s10151-011-0753-xAuthors I. Lintzeris, 2nd Surgery Department, General Hospital of Tripolis, Tripolis, GreeceX. Agrogianni, Postgraduate Medical Student, University of Athens, Athens, GreeceP. Prigouris, 4th Surgery Department, General Hospital of Athens, Greece, “Evangelismos”, Athens, GreeceA. Lintzeri, 3rd Hospital of IKA-ETAM, Athens, Athens, GreeceK. Giovannakis, 4th Surgery Department, Gene...

New HPV Vaccine Offers Protection Against Anal Cancer

Cancer Network — Thu, 01 Sep 2011 12:00:00 +0100

A study published in Lancet Oncology shows that an AS04-adjuvanted HPV 16 and HPV 18 vaccine developed by GlaxoSmithKline Biologicals can offer protection against anal cancer. (Source: Cancer Network)

Synthetic vaccine for the treatment of lesions caused by high risk human papilloma virus.

Cancer Journal — Thu, 01 Sep 2011 04:00:00 +0100

Authors: Melief CJ Abstract Until recently, therapeutic cancer vaccines only sporadically led to long-term clinical responses. We here report on a novel vaccine modality, characterized by the administration of long (23-45 amino acids) synthetic peptides in incomplete Freund adjuvant (mineral oil-based, Montanide ISA-51), delivered subcutaneously. Such vaccines were first demonstrated to be much more potent in preclinical T-cell response induction and tumor therapy experiments than short major histocompatibility complex class I-binding peptides that have been used extensively in the clinic. A long-peptide vaccine consisting of 13 overlapping peptides, together covering the entire length of the 2 oncogenic proteins E6 and E7 of high-risk human papilloma virus type 16 (HPV16), caused ...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

HPV Vaccine Update: New Indications and Controversies.

Skin Therapy Letter — Thu, 01 Sep 2011 04:00:00 +0100

Authors: Mendoza N, Hernandez PO, Tyring SK Abstract Human papillomavirus (HPV) has a predilection for infecting epidermal and mucosal surfaces such as those of the anogenital region. HPV causes substantial pre-malignant, malignant, and benign disease in both women and men, ranging from cervical, vulvar, penile, and anal cancers to condyloma acuminata (genital warts). Although HPV vaccination is becoming more common, infection rates remain high in both genders. Perception of HPV vaccine has largely centered on its ability to prevent cervical cancer in women, though indication for its use in men is expanding. The benefits to men include prevention of genital warts and, more recently, regulatory approval was expanded in the US for prevention of anal cancer. Herein, we review HPV vacc...

[Articles] Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial

The Lancet Oncology — Sat, 27 Aug 2011 13:06:57 +0100

SummaryBackgroundAnal cancer remains rare (incidence of about 1·5 per 100 000 women yearly), but rates are increasing in many countries. Human papillomavirus (HPV) 16 and 18 infections cause most cases of anal cancer. We assessed efficacy of an AS04-adjuvanted HPV 16 and HPV 18 vaccine against anal infection with HPV 16, HPV 18, or both (HPV 16/18).MethodsWomen from Costa Rica were registered between June 28, 2004, and Dec 21, 2005, in a randomised double-blind controlled trial that was designed to assess vaccine efficacy against persistent cervical HPV 16/18 infections and associated precancerous lesions. (Source: The Lancet Oncology)

[Comment] Who should be targeted for vaccination against anal cancer?

The Lancet Oncology — Sat, 27 Aug 2011 13:06:56 +0100

Although cervical cancer occurs 35 times more frequently than anal cancer in unscreened women and is the focus of prophylactic HPV vaccines, anal cancer, while unequally distributed in the population, is another HPV-associated cancer. Women have twice the incidence of anal cancer as men, participate in receptive anal intercourse (an independent risk factor for anal cancer) 2–10 times more frequently than do heterosexual men, and are predisposed to anal HPV infection if they already have cervical neoplasia, irrespective of anal intercourse. (Source: The Lancet Oncology)

Targeting HPV 16/18 shows promise in cancer risk reduction

HemOncToday.com — Fri, 26 Aug 2011 10:49:00 +0100

New vaccine provides ‘strong protection’ for anal cancer, and researchers discover that separate screening for HPV 16/18 may represent a more effective screening strategy. (Source: HemOncToday.com)

Premalignant Lesions of the Anal Canal and Squamous Cell Carcinoma of the Anal Canal

Clinics in Colon and Rectal Surgery — Thu, 25 Aug 2011 23:00:00 +0100

Clinics in Colon and Rectal Surgery 2011; 24: 177-192DOI: 10.1055/s-0031-1286002ABSTRACTSquamous cell carcinoma of the anus (SCCA) is a rare tumor. However, its incidence has been increasing in men and women over the past 25 years worldwide. Risk factors associated with this cancer are those behaviors that predispose individuals to human papillomavirus (HPV) infection and immunosuppression. Anal cancer is generally preceded by high-grade anal intraepithelial neoplasia (HGAIN), which is most prevalent in human immunodeficiency virus-positive men who have sex with men. High-risk patients may benefit from screening. The most common presentation is rectal bleeding, which is present in nearly 50% of patients. Twenty percent of patients have no symptoms at the time of presentation. Clinical stag...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Another benefit of the HPV vaccine

Health Facts and Fears — Tue, 23 Aug 2011 23:00:00 +0100

Cervarix, one of the human papillomavirus (HPV) vaccines used in innoculations against cervical cancer in girls, also appears to protect against the HPV infection responsible for most anal cancers. (Source: Health Facts and Fears)

Glaxo HPV vaccine protects women from anal cancer: study

Reuters: Health — Tue, 23 Aug 2011 12:20:20 +0100

CHICAGO (Reuters) - A vaccine to prevent cervical cancer offered strong protection against anal cancer in a large study of women in Costa Rica, adding to evidence that such vaccines can protect against more than just cervical cancer, U.S. researchers said on Monday. (Source: Reuters: Health)

HPV Vaccine Cervarix Also Protects From Anal Cancer

Health News from Medical News Today — Tue, 23 Aug 2011 03:00:00 +0100

GlaxoSmithKline's bivalent HPV vaccine Cervarix offers strong protection against anal cancer, even though it is used as a routine vaccination for girls against cervical cancer, researchers reported in The Lancet Oncology. Significant effects were noted in women who received the vaccine before exposure to the virus. Even though anal cancers are still uncommon in the general population, recent decades noted almost double the amount of cases in many countries including the USA and Europe... (Source: Health News from Medical News Today)

Glaxo HPV vaccine protects women from anal cancer: study

Reuters: Health — Mon, 22 Aug 2011 22:40:28 +0100

HPV Vaccine Protects Women Against Anal Infection (CME/CE)

MedPage Today OB/GYN — Mon, 22 Aug 2011 22:30:00 +0100

(MedPage Today) -- A vaccine against human papillomavirus (HPV) protects women against two strains of the virus that causes anal cancer, researchers reported. (Source: MedPage Today OB/GYN)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Glaxo HPV Vaccine Protects Women from Anal Cancer

MedlinePlus Health News — Mon, 22 Aug 2011 21:40:28 +0100

A vaccine to prevent cervical cancer offered strong protection against anal cancer in a large study of women in Costa Rica, adding to evidence that such vaccines can protect against more than just cervical cancer, U.S. researchers said on Monday.Source: Reuters Health Related MedlinePlus Pages: Anal Cancer, HPV (Source: MedlinePlus Health News)

SEOM clinical guidelines for the treatment of anal cancer

Clinical and Translational Oncology — Fri, 19 Aug 2011 15:56:51 +0100

Abstract Anal carcinoma is an uncommon disorder accounting for less than 2% of large bowel malignancies and 1–6% of anorectal tumours. Its incidence ranges between 0.5 and 1% per 100,000. Local staging should be done with MR imaging using an external pelvic phased-array coil. Treatment strategy should be optimally discussed in a multidisciplinary team. HIV-positive patients seem to achieve similar response rate and overall survival to HIV-negative patients but with increased toxicity and higher local recurrences. Combined modality treatment with irradiation and chemotherapy has resulted in complete response over 90% and local control over 85%. This guide gives recommendations for diagnosis, staging and treatment. Content Type Journal ArticleCategory Clinical Guides i...

HPV and precancerous lesions of anal canal in women: systematic review

International Journal of Colorectal Disease — Wed, 17 Aug 2011 06:05:55 +0100

Conclusion The existence of previous genital neoplasia associated with HPV promotes the development of anal lesions, especially in younger patients, and a poor immune status contributes to the appearance of this pathologic finding. Content Type Journal ArticleCategory ReviewPages 1-6DOI 10.1007/s00384-011-1298-1Authors Maria das Graças F. C. Castor, Pelvis Department, Cancer Hospital of Pernambuco, Av. Cruz Cabugá, 1597—Santo Amaro, Recife, Pernambuco, P.O. Box 50040-000, BrazilHilton Justino da Silva, Phonoaudiology Department, Health Sciences Centre, Federal University of Pernambuco, Av. Prof. Moraes Rego, 1235—Cidade Universitária, Recife, Pernambuco, P.O. Box: 50670-901, BrazilDanyelly Bruneska Gondim Martins, Molecular Prospecting and Bioinformatics Group...

Anal cancer treatment toxicities may require colostomy

AuntMinnie.com Headlines — Fri, 12 Aug 2011 07:00:00 +0100

Radiotherapy, with or without chemotherapy, is the preferred treatment for (more) (Source: AuntMinnie.com Headlines)

Laparoscopic Abdominoperineal Resection with Open Posterior Cylindrical Excision and Primary Transpelvic VRAM Flap

Annals of Surgical Oncology — Tue, 09 Aug 2011 05:43:47 +0100

Conclusions Our report of the operative technique shows that the combination of minimally invasive methods together with transpelvic VRAM flap transposition is technically feasible, can be performed with operative efficiency, and may become a valuable tool to minimize perioperative complications in advanced colorectal tumor surgery. Content Type Journal ArticlePages 1-2DOI 10.1245/s10434-011-1977-8Authors R. E. Horch, Department of Plastic and Hand Surgery, University of Erlangen Medical Center, Erlangen, GermanyA. D’Hoore, Department of Abdominal Surgery, University Clinics Gasthuisberg, Leuven, BelgiumT. Holm, Section of Coloproctology, Department of Surgery, Karolinska University Hospital, Stockholm, SwedenU. Kneser, Department of Plastic and Hand Surgery, Univ...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Laparoscopic Right Hepatectomy With Intrahepatic Transection of the Right Bile Duct

Annals of Surgical Oncology — Sat, 06 Aug 2011 05:57:44 +0100

Discussion Laparoscopic major hepatectomy is feasible. As in open hepatectomies, intrahepatic transection of the right bile duct may be safer because there is a decreased risk of injury to the left hepatic duct.4 , 5 Larger series with longer-term follow-up are necessary. Content Type Journal ArticlePages 1-2DOI 10.1245/s10434-011-1927-5Authors Tzu-jung Tsai, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAElie K. Chouillard, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAAndrew A. Gumbs, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA Journal Annals of Surgical OncologyOnline ISSN 1534-4681Print ISSN 1068-9265 (Source: Annals of Surgical Oncology)

FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy

British Journal of Cancer AOP — Mon, 25 Jul 2011 23:00:00 +0100

Authors: F L Day, E Link, S Ngan, T Leong, K Moodie, C Lynch, M Michael, E de Winton, A Hogg, R J Hicks & A Heriot (Source: British Journal of Cancer AOP)

Impact of pelvic radiotherapy on female sexuality

Archives of Gynecology and Obstetrics — Tue, 19 Jul 2011 06:07:30 +0100

Conclusions Our results suggested that pelvic radiotherapy had a negative impact on female sexuality. Thus, interventions that would help to reduce this impact need to be designed and integrated into routine clinical practice. Content Type Journal ArticlePages 1-10DOI 10.1007/s00404-011-1988-5Authors Ana Cláudia Rodrigues, Department of Gynecology and Obstetrics, Coimbra University Hospital, Coimbra, PortugalRubina Teixeira, Department of Radiotherapy, Coimbra University Hospital, Coimbra, PortugalTânia Teixeira, Department of Radiotherapy, Coimbra University Hospital, Coimbra, PortugalSofia Conde, Department of Radiotherapy, Coimbra University Hospital, Coimbra, PortugalPaula Soares, Department of Radiotherapy, Coimbra University Hospital, Coimbra, PortugalIsabel ...

Squamous cell carcinoma of the anus-an opportunistic cancer in HIV-positive male homosexuals.

World Journal of Gastroenterology : WJG — Wed, 06 Jul 2011 23:00:00 +0100

Authors: Gervaz P, Calmy A, Durmishi Y, Allal AS, Morel P Squamous cell carcinoma of the anus (SCCA) is a common cancer in the human immunodeficiency virus (HIV)-infected population, and its incidence continues to increase in male homosexuals. Combined chemoradiation with mitomycin C and 5-fluorouracil was poorly tolerated by severely immunocompromised patients in the early 1990s. In the era of highly active antiretroviral therapy (HAART), however, recent data indicate that: (1) most HIV patients with anal cancer can tolerate standard chemotherapy regimens; and (2) this approach is associated with survival rates similar to those of HIV-negative patients. However, HIV-positive patients with SCCA are much younger, more likely to develop local tumor recurrence, and ultimately die from ana...

The value of high-resolution anoscopy in the diagnosis of anal cancer precursor lesions in hiv-positive patients

Arquivos de Gastroenterologia — Wed, 22 Jun 2011 17:46:13 +0100

CONCLUSION: High-resolution anoscopy demonstrated to be a sensitive, but not specific test for the detection of anal squamous intraepithelial lesions. Risk factors anal receptive sex and anal HPV infection were significantly associated to the presence of anal squamous intraepithelial lesions. Based on high-resolution anoscopy image data, acetowhite lesions relief and surface pattern were prone to distinguish between low-grade squamous intraepithelial lesions and high-grade squamous intraepithelial lesions.CONTEXTO: O câncer anal, muito embora ainda seja uma doença rara, vem sendo observado com frequência ascendente em alguns grupos populacionais considerados sob risco para o desenvolvimento da doença. Infecção pelo vírus do papiloma humano (HPV), imunossupressão e o sexo anorecepti...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Cancer Screening in Patients Infected with HIV

Current HIV/AIDS Reports — Wed, 22 Jun 2011 06:06:16 +0100

Abstract Non–AIDS-defining cancers are a rising health concern among HIV-infected patients. Cancer screening is now an important component of health maintenance in HIV clinical practice. The decision to screen an HIV-infected patient for cancer should include an assessment of individualized risk for the particular cancer, life expectancy, and the harms and benefits associated with the screening test and its potential outcome. HIV-infected patients are at enhanced risk of several cancers compared to the general population; anal cancer, hepatocellular carcinoma, Hodgkin’s lymphoma, and lung cancer all have good evidence demonstrating an enhanced risk in HIV-infected persons. A number of cancer screening interventions have shown benefit for specific cancers in the general...

Farrah Fawcett cancer tied to stress? Maybe, says Ryan O'Neal

Health News: CBSNews.com — Tue, 21 Jun 2011 17:26:34 +0100

Actor says family turmoil may have contributed to actress's anal cancer diagnosis (Source: Health News: CBSNews.com)

How does Africa tackle cervical cancer?

Guardian Unlimited Science — Mon, 20 Jun 2011 07:00:00 +0100

Cancer kills more people worldwide that AIDS, tuberculosis, and malaria together - but most of Africa doesn't even have a word for it. So where should Africa's medical profession start in the bid to increase screening?Débora Miranda welcomes your help and feedback in her research. She can be contacted on Twitter @debmir and via email on cancerscreeningproject@gmail.comThere are more than 200 dialects spoken in Africa, but most of them have no word for "cancer", and this despite the fact the disease kills more people worldwide than AIDS, tuberculosis and malaria together, and the burden is particularly acute in the developing world. Cervical cancer is the second most common cancer among women here, exacerbated by the lack of reproductive health information for women and delayed access to t...

A Regimen of Taxol, Ifosfamide, and Platinum for Recurrent Advanced Squamous Cell Cancer of the Anal Canal

Diagnostic and Therapeutic Endoscopy — Thu, 16 Jun 2011 14:20:13 +0100

The typically recommended chemotherapy options in metastatic anal cancer generally yield partial remissions with limited benefit for the majority of patients. TIP is a regimen containing paclitaxel (Taxol), ifosfamide, and cisplatin that is known to have significant activity in patients with squamous cell cancers of the head and neck as well as in cervical cancer, both of which are malignancies strongly associated with oncogenic strains of human papilloma virus (HPV). Interestingly, squamous cell cancer of the anal canal shares an almost identical pathophysiology including causal association with HPV. Due to this, we chose to use the TIP regimen to treat patients with advanced anal cancer at our institution and report our findings on three such consecutive patients. All the patients tolera...

The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series

Anesthesiology Research and Practice — Mon, 13 Jun 2011 14:17:40 +0100

We present three cases of refractory anal cancers, treated with EGFR inhibitors, after having received the recommended chemotherapy regimens. We conclude that EGFR inhibitors may play a vital role in the treatment of anal cancer and we suggest that large trials are be conducted in order to clarify their efficacy and to improve therapeutic management. (Source: Anesthesiology Research and Practice)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Female sexual function after abdominoperineal resection for squamous cell carcinoma of the anus and the specific influence of colpectomy and vertical rectus abdominis myocutaneous flap

Colorectal Disease — Fri, 10 Jun 2011 16:44:42 +0100

Conclusion Among women who had SL before APR, 76% still had sexual intercourse after. Colpectomy seems to reduce SL. (Source: Colorectal Disease)

Unique Clinical Trial Addresses Important Questions About Treating Cancer In Those With HIV

Health News from Medical News Today — Tue, 07 Jun 2011 12:00:00 +0100

As the world marks the 30-year anniversary of the first reporting of HIV/AIDS, now comes the realization of a new challenge for people with the incurable disease. For reasons not yet clear, people with HIV face a higher rate of cancers not usually associated with HIV. This increasing rate of "non-AIDS defining cancers" includes lung, head and neck, liver, kidney, and anal cancers, among others. The alarming uptick in cancer rates highlights the critical need to understand how to treat tumors in people taking highly active anti-retroviral therapy (HAART) for HIV... (Source: Health News from Medical News Today)

Should boys be vaccinated against the human papilloma virus (HPV)?

Guardian Unlimited Science — Fri, 27 May 2011 17:59:51 +0100

HPV not only causes cervical cancer in women, it is also related to more rare types of cancer in menDébora welcomes your help and feedback in her research. She can be contacted on Twitter @debmir and via email on cancerscreeningproject@gmail.comLast week I reviewed the main differences between the Cervarix and the Gardasil vaccines. As well as protecting against cancer-causing HPV strains 16 and 18, Gardasil prevents strains 6 and 11, which cause genital warts. For public health authorities, choosing which vaccine to adopt is a complex matter, with scientific, economic and cultural dimensions.Britain's NHS vaccine programme uses Cervarix, but which vaccine would doctors choose for their own daughters?GP and writer Dr Phil Hammond asked various colleagues this question. Peter Greenhouse, f...

Incidence of Non-AIDS-Defining Cancer in Antiretroviral Treatment-Naïve Subjects after Antiretroviral Treatment Initiation: An ACTG Longitudinal Linked Randomized Trials Analysis.

Oncology — Sun, 22 May 2011 23:00:00 +0100

Conclusion: Smoking and lower recent CD4 levels, but not initial ART drug class, were associated with NADC. Strategies for maintaining higher CD4 cell counts and successful smoking cessation may reduce the NADC incidence in the HIV-infected population. PMID: 21606663 [PubMed - as supplied by publisher] (Source: Oncology)

Cancer Burden in the HIV-Infected Population in the United States

JNCI — Mon, 02 May 2011 23:00:00 +0100

Conclusions Over a 15-year period (1991–2005), increases in non-AIDS-defining cancers were mainly driven by growth and aging of the AIDS population. This growing burden requires targeted cancer prevention and treatment strategies. (Source: JNCI)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Outcomes of salvage surgery for epidermoid carcinoma of the anus following failed combined modality treatment

American Journal of Surgery — Sat, 30 Apr 2011 23:00:00 +0100

Conclusions: Recurrent anal carcinoma after primary chemoradiotherapy carries a poor prognosis. Salvage abdominoperineal resection offers a potential for long-term survival. (Source: American Journal of Surgery)

Long-Term Follow-Up of a Phase II Trial of High-Dose Radiation With Concurrent 5-Fluorouracil and Cisplatin in Patients With Anal Cancer (ECOG E4292)

International Journal of Radiation Oncology * Biology * Physics — Thu, 21 Apr 2011 04:00:00 +0100

Conclusions: Radiation therapy, cisplatin, and 5-FU resulted in an overall objective response (complete response + partial response) of 97%. Although the 5-year progression-free survival was only 55%, the overall 5-year survival was 69%. Given the excellent salvage provided by surgery, this study affirms that cisplatin-based regimens may be an alternative for patients who cannot tolerate the severe hematologic toxicities associated with mitomycin-based chemoradiation regimens. (Source: International Journal of Radiation Oncology * Biology * Physics)

Trends in incidence of anal cancer and high‐grade anal intraepithelial neoplasia in Denmark, 1978–2008

International Journal of Cancer — Mon, 04 Apr 2011 23:00:00 +0100

AbstractThe aim of the study was to determine the incidences of anal cancer and high‐grade anal intraepithelial neoplasia (AIN2/3) over time in Danish women and men. Describing the burden of anal cancer and AIN may be valuable in future evaluations of the human papillomavirus (HPV) vaccine. We included all anal cancers in the Danish Cancer Register in the period 1978–2008 and all cases of AIN2/3 in the Danish Registry of Pathology. Overall and age‐, period‐ and histology‐specific incidence rates were estimated. During the 30‐year period, 2187 anal cancers were identified, two thirds of which were in women. Between 1978–1982 and 2003–2008, the age‐standardized incidence rate of anal cancer increased from 0.68 to 1.48 per 100 000 person–years in women and from 0.45 to 0.8...

Rethinking the head and neck cancer population.

Clinical Journal of Oncology Nursing — Thu, 31 Mar 2011 23:00:00 +0100

Authors: Callaway C Head and neck squamous cell carcinoma (HNSCC) is the tenth most commonly diagnosed form of cancer in males worldwide. Although the incidence of HNSCC is relatively low in the United States, the affected population is changing from older males to young Caucasian males. High-risk strains of the human papillomavirus (HPV) already are associated with cervical, oral, and anal cancers; however, HPV DNA has been detected in about a third of head and neck malignancies. Nurses play major roles in educating the public and treating patients with HPV and HNSCC. Many possibilities for outreach and research exist that could decrease HPV and HNSCC rates. PMID: 21444283 [PubMed - in process] (Source: Clinical Journal of Oncology Nursing)

Chemotherapy/chemoradiation in anal cancer: A systematic review

Cancer Treatment Reviews — Tue, 29 Mar 2011 23:00:00 +0100

Conclusions: In anal cancer T3/T4 lesions fare badly (3year DFS 40–68%). Cisplatin appears an effective drug, but novel strategies have not allowed progress from the schedule of chemoradiation using MMC, infusional 5FU and radiotherapy – the paradigm developed by Nigro over 30years ago. Different cytotoxic agents such as capecitabine, oxaliplatin and docetaxel, and biologically targeted agents – either an EGFR monoclonal antibody or an oral tyrosine kinase inhibitor, which exploits this pathway, might offer an alternative. In particular, the role of EGFR inhibition following chemoradiation should be explored. (Source: Cancer Treatment Reviews)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Initial Experience with Topical Fluorouracil for Treatment of HIV-Associated Anal Intraepithelial Neoplasia

Journal of the International Association of Physicians in AIDS Care (JIAPAC) — Thu, 24 Mar 2011 00:00:00 +0100

Exposure to high-risk strains of human papillomavirus (HPV) promotes cellular dysplasia of the anal canal epithelium, potentially leading to anal intraepithelial neoplasia (AIN), which is in turn a precursor to invasive squamous cell carcinoma of the anus (SCCA). People with HIV infection who engage in anoreceptive intercourse are at heightened risk for acquiring HPV, AIN, and SCCA. Although intravenous 5-fluorouracil (5-FU) is commonly used for treatment of invasive SCCA, there has been little experience with the use of topical 5-FU as therapy for AIN. We retrospectively reviewed records of the first 11 HIV-positive patients treated with topical 5-FU in our anal dysplasia clinic. Six (55%) patients had clinical improvement with reduction in area of dysplasia seen on high-resolution anosco...

Assessment of the implementation and knowledge of the UK National Guidelines for HIV Testing (2008) in key conditions at a UK district general hospital

International Journal of STD and AIDS — Tue, 22 Mar 2011 00:00:00 +0100

The objective of this study is to audit the implementation and knowledge of the British HIV Association (BHIVA) UK National guidelines for HIV testing (2008) in key conditions at Basildon & Thurrock University Hospital. Basildon Hospital is a district general hospital, serving over 400,000 patients in south-west Essex. A total of 348 patients were assessed through electronic to pathology data and patients' notes to investigate if they had been tested for HIV when diagnosed with the following conditions: tuberculosis (TB), hepatitis B and C, cervical intraepithelial neoplasia grade II/III, lymphoma, anal cancer, seminoma or Castleman's disease. The physicians involved were questioned as to their knowledge of the HIV testing guidelines. Of the 348 patients who were identified as having t...

Humoral hypercalcaemia of malignancy associated with squamous cell carcinoma of the anus

Colorectal Disease — Thu, 17 Mar 2011 00:00:00 +0100

(Source: Colorectal Disease)

An Update to the Society for Adolescent Health and Medicine's Position Statement on the Human Papillomavirus Vaccine

Journal of Adolescent Health — Tue, 15 Mar 2011 23:06:38 +0100

In December 2010, the Food and Drug Administration expanded its indication of the quadrivalent human papillomavirus (HPV) vaccine to prevent anal cancer caused by HPV types 16 and 18, and to prevent anal intraepithelial neoplasia caused by HPV types 6, 11, 16, and 18. (Source: Journal of Adolescent Health)

Anal Cancer: An Examination of Radiotherapy Strategies

International Journal of Radiation Oncology * Biology * Physics — Tue, 15 Mar 2011 18:28:05 +0100

The Radiation Therapy Oncology Group 9811, ACCORD-03, and ACT II Phase III trials in anal cancer showed no benefit for cisplatin-based induction and maintenance chemotherapy, or radiation dose-escalation >59 Gy. This review examines the efficacy and toxicity of chemoradiation (CRT) in anal cancer, and discusses potential alternative radiotherapy strategies. The evidence for the review was compiled from randomized and nonrandomized trials of radiation therapy and CRT. A total of 103 retrospective/observational studies, 4 Phase I/II studies, 16 Phase II prospective studies, 2 randomized Phase II studies, and 6 Phase III trials of radiotherapy or chemoradiation were identified. There are no meta-analyses based on individual patient data.A “one-size-fits-all” approach for all stages of ana...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Optimising Treatment of Anal Cancer: 3D Conformal Radiotherapy with Concurrent Mitomycin C and Capecitabine

Clinical Oncology — Tue, 15 Mar 2011 18:27:16 +0100

Introduction: The ACT-II trial confirmed mitomycin C with 5-FU as the standard of care for anal cancer when combined with conventionally planned radiotherapy. Capecitabine is widely used as an oral alternative to 5-FU in gastrointestinal cancer with encouraging preliminary results for anal cancer. Modern radiotherapy techniques allow greater dose shaping than with fields selected on the basis of macroscopic disease and bony anatomy. We sought to assess the toxicity and efficacy of a new regime using mitomycin C with capecitabine and conformally planned radiotherapy. (Source: Clinical Oncology)

Organ Sparing IMRT for Anal Cancer using ACTII Schedule: a Comparison of Conventional and IMRT Plans

Clinical Oncology — Tue, 15 Mar 2011 18:27:11 +0100

Background and purpose: The use of conventional external-beam radiotherapy (CRT) for anal cancer is associated with a high rate of treatment-related morbidity. The purpose of this study was to compare the dosimetric advantages of two intensity-modulated radiotherapy (IMRT) plans to CRT with regards to organs at risk (OAR) avoidance delivering 50.4 Gy in 1.8 Gy/fraction: 19 fractions for phase 1 and 11 fractions for phase 2. (Source: Clinical Oncology)

Anal Cancer Risk Increased With HPV-Related Gynecologic Neoplasms

Medscape ObGyn and Womens Health Headlines — Wed, 02 Mar 2011 20:40:21 +0100

Gynecologic neoplasms due to human papilloma virus (HPV) can significantly increase a woman's risk of anal cancer, according to a report in the March issue of Obstetrics & Gynecology. Reuters Health Information (Source: Medscape ObGyn and Womens Health Headlines)

Risk of anal cancer in a cohort with human papillomavirus-related gynecologic neoplasm.

Obstetrics and Gynecology — Tue, 01 Mar 2011 00:00:00 +0100

Authors: Saleem AM, Paulus JK, Shapter AP, Baxter NN, Roberts PL, Ricciardi R : To assess the development of anal cancer in women diagnosed with a human papillomavirus-related cervical, vulvar, or vaginal neoplasm. PMID: 21343768 [PubMed - in process] (Source: Obstetrics and Gynecology)

Diagnosis and Treatment of Anal Intraepithelial Neoplasia and Condylomata

Seminars in Colon and Rectal Surgery — Tue, 01 Mar 2011 00:00:00 +0100

Anal human papilloma virus (HPV) infection causes significant pathology, including condylomata as well as low- and high-grade anal intraepithelial lesions, the precursors of invasive cancer. Men who have sex with men, women with concomitant high-grade cervical/vulvar disease, and immunocompromised patients are particularly vulnerable. The incidence of anal cancer is increasing in men and women, but human immunodeficiency virus-infected patients regardless of immune reconstitution are at greatest risk. A critical review of the literature and evidence-based, comparative analysis and discussion of treatment modalities for anal HPV related diseases was undertaken. Anal cytology screening for high-grade dysplasia has been shown to be sensitive and cost-effective in men who have sex with men; an...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Type of Radiation Used Affects Response in Anal Cancer

Modern Medicine — Mon, 28 Feb 2011 00:00:00 +0100

In patients with anal canal squamous cell carcinoma, intensity-modulated radiation therapy is associated with less toxicity, fewer and shorter treatment breaks, and good overall survival and locoregional control compared with conventional radiotherapy, according to a study published online Feb. 1 in Cancer. (Source: Modern Medicine)

Performance of p16INK4a immunocytochemistry as a marker of anal squamous intraepithelial lesions

Cancer Cytopathology — Fri, 25 Feb 2011 00:00:00 +0100

CONCLUSIONS:There was no association between ICCp16 results and histopathological findings nor between ICCp16 and HPV genotyping. ICCp16 showed poor sensitivity and moderate specificity for the diagnosis of ASIL or high‐risk HPV. Cancer (Cancer Cytopathol) 2011. © 2011 American Cancer Society. (Source: Cancer Cytopathology)

Carcinoma of the anal canal: State of art, issues in geriatric oncology and molecular targeted therapies.

Bulletin du Cancer — Fri, 25 Feb 2011 00:00:00 +0100

Authors: Hau Desbat NH, Auberdiac P, Chargari C, Merrouche Y, Deutsch E, Schmitt T, de Laroche G, Magné N Since the 1990, chemoradiation has become the standard treatment for locally advanced anal cancer. Recent progress in molecular biology and the growing number of elderly patients invite the clinicians to personalize the multimodal therapy strategy. However, data about anal cancer and elderly patients or targeted therapy are extremely sparse. Indeed, national or international guidelines don't mention these two subjects. The purpose of this article is to make the state of art of the management of anal cancer and its interferences with geriatrics and molecular targeted therapy. PMID: 21382795 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)

Quality of Life Outcomes in Patients with Anal Cancer after Combined Radiochemotherapy

Strahlentherapie und Onkologie — Wed, 23 Feb 2011 23:33:43 +0100

Conclusion: The global health QoL of anal cancer patients is comparable with that of the general German population, but there are specific limitations, e.g., sexual dysfunction, urological/gastrointestinal complaints, financial difficulties, fatigue, and a reduction in emotional and social well-being. Content Type Journal ArticlePages 1-8DOI 10.1007/s00066-010-2175-5Authors Grit Welzel, Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, GermanyVerena Hägele, Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, GermanyFrederik Wenz, Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, GermanySabine Kathrin...

Anal Warts and Anal Intradermal Neoplasia

Clinics in Colon and Rectal Surgery — Wed, 23 Feb 2011 00:00:00 +0100

Clinics in Colon and Rectal Surgery 2011; 24: 031-038DOI: 10.1055/s-0031-1272821ABSTRACTFor the last five millennia we have been dealing with the annoyance of verrucas. Anogenital human papillomavirus (HPV) infection is the most common sexually transmitted disease in the United States and is increasing in incidence. As in other gastrointestinal conditions, HPV infection can lead to a stepwise transition from normal cells to dysplastic cells and then to invasive anal cancer. Knowledge of the natural history of HPV infection, risk factors, diagnostic tools, and therapeutic methods gives us the tools to adequately prevent, evaluate, treat, and counsel our patients. In this review, the authors detail the diagnosis, management, and treatment of anal condyloma and anal intraepithelial neoplasia ...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Epidemiology of vulvar and vaginal cancer in Germany

Archives of Gynecology and Obstetrics — Mon, 21 Feb 2011 17:07:01 +0100

Conclusions Due to a change in sexual behavior and an increased rate of HPV infection among younger women, increased incidence of both diseases has to be expected. The age-standardized mortality rate of vulvar carcinoma in Europe is stated at 0.7/100,000 women, and that of vaginal carcinoma at 0.4/100.000 women. To what extent the HPV-vaccination affects incidence and mortality rates is continually being observed. Content Type Journal ArticlePages 1-6DOI 10.1007/s00404-011-1850-9Authors C. Dittmer, Department of Obstetrics and Gynaecology, University Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, GermanyA. Katalinic, Institute of Cancer Epidemiology, University of Lübeck, Beckergrube 43-47, 23552 Lübeck, GermanyC. Mundhen...

Scientist urges human papilloma virus jabs for boys to stem oral cancer rise

Guardian Unlimited Science — Sun, 20 Feb 2011 16:06:00 +0100

HPV, usually associated with cervical cancer, linked to throat and mouth tumoursBoys should be considered for routine vaccination against the human papilloma virus (HPV) to stem the rise of some oral cancers, according to a leading scientist working on the disease. The recommendation comes after studies which show that oral cancers in the young are more commonly caused by HPV than by more traditional factors such as tobacco and alcohol.HPV is normally associated with cervical cancer in women, but evidence has increased in recent years that it can infect tonsils and lead to tumours in the throat and mouth. In the UK, the incidence of oral cancers has risen by 50% in men since 1989 and is rising by 3% a year in women, even though smoking, once thought to be the main cause, is declining. Thes...

Anal Cancer: Focus on HIV-Positive Patients in the HAART-Era.

Current HIV Research — Tue, 15 Feb 2011 00:00:00 +0100

Authors: Zanet E, Berretta M, Martellotta F, Cacopardo B, Fisichella R, Tavio M, Berretta S, Tirelli U Anal cancer represents an increasing health problem, especially in immune-compromised patients, as HIV-positive patients. Notably, a significant higher incidence rate is reported among HIV infected patients with the advent of highly active antiretroviral therapy (HAART). To date, no randomised trial supports the correlation between existing screening strategies and reduced progression of anal intraepithelial neoplasia (AIN) to anal cancer or improved survival. Nevertheless, screening and treatment of AIN by topical agents should be implemented in high risk population. Data on invasive anal cancer treatment show that combined modality treatment (CMT) is the treatment of choice. Early r...

HPV vaccine also protects against anal cancer

Health Facts and Fears — Thu, 10 Feb 2011 00:00:00 +0100

Yesterday’s The New York Times underscored the risks associated with anal cancer — facts largely unknown to many U.S. adults. (Source: Health Facts and Fears)

Well: Saving Lives From Anal Cancer

NYT Health — Wed, 09 Feb 2011 17:56:15 +0100

After their mother died of anal cancer, her children established a foundation to raise awareness of the disease. (Source: NYT Health)

MedWorm Sponsor Message: Find the best January Sales in the UK.

IMRT produced less toxicity, similar outcomes as conventional radiation in anal cancer

HemOncToday.com — Fri, 04 Feb 2011 15:29:23 +0100

(Source: HemOncToday.com)

Anal cancer precursor lesions in HIV-positive and HIV-negative patients seen at a tertiary health institution in Brazil.

Acta Cirurgica Brasileira — Tue, 01 Feb 2011 00:00:00 +0100

Conclusions: In the patients studied, ASIL (low and/or high-grade) tended to be significantly more prevalent in HIV-positive patients. Nonetheless, HIV-negative anoreceptive patients also presented great probability to have anal cancer precursor lesions, mainly those of the male gender. PMID: 21271206 [PubMed - in process] (Source: Acta Cirurgica Brasileira)

[Verrucous carcinoma of the anal margin. The importance of adequate biopsy technique.]

Orvosi Hetilap — Tue, 01 Feb 2011 00:00:00 +0100

Authors: Soós Z, Varga T, Vadinszky P, Hajós P, Vajda K, Kiss S, Winkler G Buschke-Löwenstein tumor (verrucous carcinoma, giant condylomata) of the anal margin is a locally invasive, destructively growing carcinoma that does not metastasize. The lesions are rare despite the increased incidence of anal condylomata and anal carcinomas. Authors report a case of a 63-year-old woman suffering from verrucous carcinoma (Buschke-Löwenstein tumor) of the anal margin. The tumor invaded the rectal sphincter and extended beyond the muscle, infiltrating the lower abdomen. Infiltration of the perivesical soft tissue caused bilateral hydronephros. Because both under- and overdiagnosis of anal cancer and precancer may lead to inappropriate treatment, it is important to perform adequate sampling fo...

IMRT reduces acute toxicities to anal cancer patients

AuntMinnie.com Headlines — Thu, 27 Jan 2011 07:00:00 +0100

Using intensity-modulated radiation therapy (IMRT) instead of conventional (more) (Source: AuntMinnie.com Headlines)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

IMRT for Anal Cancer Associated With Fewer Adverse Events

Medscape Today Headlines — Wed, 19 Jan 2011 21:05:58 +0100

Without affecting 2-year outcomes, intensity-modulated radiation therapy (IMRT) had fewer adverse events than conventional radiation therapy. Medscape Medical News (Source: Medscape Today Headlines)

ASCO GI: IMRT Cuts Severe Toxicity in Anal Cancer

MedPage Today Gastroenterology — Wed, 19 Jan 2011 14:43:03 +0100

SAN FRANCISCO (MedPage Today) -- Intensity-modulated radiation therapy (IMRT) for anal cancer did not reduce the overall toxicity of conventional radiation but did minimize the most serious adverse effects with similar tumor control, investigators reported. (Source: MedPage Today Gastroenterology)

IMRT produced similar outcomes, less toxicity as conventional radiation in anal cancer

HemOncToday.com — Tue, 18 Jan 2011 09:08:00 +0100

(Source: HemOncToday.com)

Improving Anal Cancer Screening in an Ambulatory HIV Clinic: Experience from a Quality Improvement Initiative

AIDS Patient Care and STDs — Sun, 16 Jan 2011 00:28:31 +0100

AIDS Patient Care and STDs , Vol. 0, No. 0. (Source: AIDS Patient Care and STDs)

A Double-blind, Randomized Controlled Trial of the Use of Imiquimod Cream for the Treatment of Anal Canal High-grade Anal Intraepithelial Neoplasia in HIV-positive MSM on HAART, With Long-term Follow-up Data Including the Use of Open-label Imiquimod

Medscape Hiv-Aids Headlines — Thu, 13 Jan 2011 19:49:11 +0100

What is the most effective treatment for anal cancer? AIDS (Source: Medscape Hiv-Aids Headlines)

MedWorm Sponsor Message: Find the best January Sales in the UK.

FDA approves Gardasil for anal cancer prevention

Drug Topics - Top News — Thu, 06 Jan 2011 00:00:00 +0100

FDA has approved Gardasil (Merck) for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 in individuals aged 9 through 26 years. (Source: Drug Topics - Top News)

FDA approves Gardasil to prevent anal cancer

Modern Medicine — Wed, 05 Jan 2011 00:00:00 +0100

The Food and Drug Administration (FDA) has approved Gardasil (human papillomavirus [HPV] quadrivalent vaccine, recombinant; Merck) for the prevention of anal cancer and associated precancerous lesions due to HPV types 6, 11, 16 and 18 in people ages 9 through 26 years, PRNewswire-USNewswire reports. (Source: Modern Medicine)

The spectrum of malignancies in HIV‐infected patients in 2006 in France: The ONCOVIH study

International Journal of Cancer — Tue, 04 Jan 2011 00:00:00 +0100

AbstractSince no large descriptive studies of incident cancers in HIV‐infected patients are available in France, the nationwide cross‐sectional ONCOVIH study aimed to prospectively report new malignancies diagnosed in HIV‐infected patients in cancer centers and HIV/AIDS centers. We estimated the number of cancers in France for the year 2006 using the capture‐recapture methods with two sources: ONCOVIH and the FHDH ANRS‐CO4 cohort, as well as the completeness of the sources. Incidence and relative risks (RR) to the general population were estimated.In 2006, 672 new malignancies in 668 patients were reported in ONCOVIH; the most common were non Hodgkin's lymphoma (NHL, 21.5%), Kaposi's sarcoma (KS, 16.0%), lung cancer (9.4%), anal cancer (8.2%), Hodgkin's lymphoma (7.6%), skin canc...

Docking and Molecular Dynamics Study on the Inhibitory Activity of Novel Inhibitors on Epidermal Growth Factor Receptor (EGFR).

Medicinal Chemistry — Sat, 01 Jan 2011 00:00:00 +0100

Authors: Liao QH, Gao QZ, Wei J, Chou KC EGFR is the cell-surface receptor. Its overexpression or overactivity has been associated with a number of cancers, including breast, lung, ovarian, and anal cancers. Many therapeutic approaches are aimed at the EGFR. A series of 2, 7-diamino-thiazolo [4,5-d] pyrimidine analogues are among the most highly potent and selective inhibitors of EGFR described to date. For in-depth investigation into the structural and chemical features responsible for the binding recognition mechanism concerned, as well as for exploring the binding pocket of these compounds, we performed a series of automated molecular docking operations. It was revealed that the binding site consisted of three main areas (P1, P2 and P3) composed of most of the hydrophobic amino acid...

FDA approves Gardasil for prevention of anal cancer

Modern Medicine Contemporary Pediatrics — Wed, 29 Dec 2010 00:00:00 +0100

The US Food and Drug Administration (FDA) has approved use of the vaccine Gardasil in the population ages 9 through 26 years for the prevention of anal cancer and anal intraepithelial neoplasia (AIN) precancerous lesions grades 1, 2, and 3 caused by human papillomavirus (HPV) types 6, 11, 16, and 18. (Source: Modern Medicine Contemporary Pediatrics)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

FDA approves Gardasil as a vaccine against anal cancer

Health Facts and Fears — Wed, 29 Dec 2010 00:00:00 +0100

The FDA announced yesterday that it has approved Gardasil, Merck’s vaccine against four common strains of human papillomavirus (HPV), for the prevention of anal cancer. Gardasil was already approved as a vaccine to prevent cervical, vulvar and vaginal cancers and genital warts. (Source: Health Facts and Fears)

HPV Vaccine Approved to Prevent Anal Cancer

About AIDS / HIV — Wed, 29 Dec 2010 00:00:00 +0100

Gardasil, the HPV vaccine approved for the prevention of HPV related cervical cancer has now been approved by the Food and Drug Administration (FDA) to be used to prevent anal cancer in people age 9 to 26 years. Many people believe anal cancer is only a problem in gay men due to anal sex. However, women can get HPV related anal cancer as well. In fact, the American Cancer Society estimates that there are 5300 new cases of anal cancer each year with more women being diagnosed than men. Anal cancer is still uncommon in the general population but the incidence is on the rise with 90% of cases being related to HPV. Experts note that Gardasil will not impact precancerous lesions already present at the time of vaccination. Also, for the maximum affect of Gardasil, people should be vaccinated pri...

FDA, Gardasil Approved To Prevent Anal Cancer

Health News from Medical News Today — Tue, 28 Dec 2010 09:00:00 +0100

The U.S. Food and Drug Administration approved the vaccine Gardasil for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 in people ages 9 through 26 years. Gardasil already is approved for the same age population for the prevention of cervical, vulvar, and vaginal cancer and the associated precancerous lesions caused by HPV types 6, 11, 16, and 18 in females. It is also approved for the prevention of genital warts caused by types 6 and 11 in both males and females... (Source: Health News from Medical News Today)

Gardasil approval expanded to include anal cancer

USATODAY.com Health — Sat, 25 Dec 2010 20:00:00 +0100

U.S. Food and Drug Administration approval of Gardasil (human papillomavirus vaccine) has been widened to include prevention of anal cancer and ... (Source: USATODAY.com Health)

Vaccine to prevent anal cancer approved in U.S.

CBC | Health — Fri, 24 Dec 2010 20:19:19 +0100

The Gardasil vaccine has received the regulatory green light in the U.S. to prevent anal cancer. (Source: CBC | Health)

MedWorm Sponsor Message: Find the best January Sales in the UK.

FDA approves vaccine for anal cancer

Health News - UPI.com — Thu, 23 Dec 2010 22:13:04 +0100

WASHINGTON, Dec. 23 (UPI) -- The U.S. Food and Drug Administration says it has approved a vaccine to prevent anal cancer caused by the human papilloma virus. (Source: Health News - UPI.com)

Health Buzz: FDA Approves Gardasil for Anal Cancer

U.S. News - Health — Thu, 23 Dec 2010 16:19:00 +0100

Tips to cure a hangover; holiday foods that are good for you. (Source: U.S. News - Health)

Gardasil Approved to Prevent Anal Cancer

MedlinePlus Health News — Thu, 23 Dec 2010 16:17:13 +0100

Source: Food and Drug Administration Related MedlinePlus Page: Anal Cancer (Source: MedlinePlus Health News)

Human Papilloma Virus: FDA Okays Vaccine for Anal Cancer

Health News: CBSNews.com — Thu, 23 Dec 2010 14:43:49 +0100

Four of Five Cases of Anal Cancer Caused by HPV, Same Virus that Causes Genital Warts (Source: Health News: CBSNews.com)

FDA Expands Approval Of HPV Vaccine Gardasil

Drugs.com - Pharma News — Thu, 23 Dec 2010 14:26:00 +0100

From Associated Press (December 22, 2010) SILVER SPRING, Md. -- The Food and Drug Administration on Wednesday further expanded marketing approval for Merck & Co.’s vaccine Gardasil, clearing the vaccine for the prevention of anal cancer... (Source: Drugs.com - Pharma News)

FDA Approves Gardasil For Anal Cancer Prevention

Health News from Medical News Today — Thu, 23 Dec 2010 10:00:00 +0100

Gardasil is now approved as a vaccine for preventing anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18, in males and females from 9 to 26 years old, said the The US Food and Drug Administration on Wednesday. Human papillomavirus (HPV) is a sexually transmitted infection that usually causes genital warts, but it can also cause several cancers such as cervical cancer in women and anal cancer in both men and women, and precancerous lesions... (Source: Health News from Medical News Today)

Gardasil Approved for Anal Cancer Prevention

eMedicineHealth.com — Thu, 23 Dec 2010 07:00:00 +0100

(Source: eMedicineHealth.com)

US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL(R)

HSMN NewsFeed — Thu, 23 Dec 2010 03:03:04 +0100

GARDASIL now Approved for Prevention of Anal Cancer and AIN WHITEHOUSE STATION, N.J.--(Healthcare Sales & Marketing Network)-- Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has... Biopharmaceuticals, Oncology, FDAMerck, GARDASIL, Papillomavirus, HPV Vaccine (Source: HSMN NewsFeed)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Gardasil Gets FDA Nod for Prevention of Anal Cancer

Medscape Today Headlines — Thu, 23 Dec 2010 00:38:43 +0100

Already approved for the prevention of cervical, vulvar, and vaginal cancer, Gardasil is now approved for the prevention of anal cancer by the FDA in human papillomavirus types 6, 11, 16, and 18. Medscape Medical News (Source: Medscape Today Headlines)

Breaking News: FDA approves Gardasil for anal cancer prevention

Drug Topics - Top News — Thu, 23 Dec 2010 00:00:00 +0100

Gardasil Approved for Anal Cancer Prevention

WebMD Health — Wed, 22 Dec 2010 23:33:50 +0100

The FDA today approved the Gardasil vaccine against sexually transmitted HPV for preventing anal cancer in both males and females. Routine HPV vaccination is recommended for girls but optional for boys. (Source: WebMD Health)

Merck's Gardasil wins approval for anal cancer

Reuters: Health — Wed, 22 Dec 2010 21:21:35 +0100

NEW YORK (Reuters) - Merck & Co's Gardasil vaccine won U.S. approval on Wednesday for preventing anal cancer, providing a new weapon against a rare but rising form of the disease. (Source: Reuters: Health)

Gardasil Approval Expanded to Include Anal Cancer

The Doctors Lounge - Oncology — Wed, 22 Dec 2010 21:00:00 +0100

Among people aged 9 to 26 (Source: The Doctors Lounge - Oncology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

FDA Approves HPV Vax to Prevent Anal Cancer

MedPage Today Pediatrics — Wed, 22 Dec 2010 20:13:07 +0100

WASHINGTON (MedPage Today) -- The FDA has approved the human papillomavirus vaccine Gardasil for use in males and females ages 9 to 26 to prevent anal cancer. (Source: MedPage Today Pediatrics)

FDA: Gardasil Approved to Prevent Anal Cancer

Drugs.com - New Drug Approvals — Wed, 22 Dec 2010 20:12:32 +0100

The U.S. Food and Drug Administration today approved the vaccine Gardasil for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 in people ages 9 through 26 years. Gardasil is... (Source: Drugs.com - New Drug Approvals)

FDA: Gardasil approved to prevent anal cancer

Food and Drug Administration — Wed, 22 Dec 2010 20:10:00 +0100

Gardasil Approval Expanded to Include Anal Cancer

MedlinePlus Health News — Wed, 22 Dec 2010 20:00:00 +0100

Among people aged 9 to 26Source: HealthDay Related MedlinePlus Pages: Anal Cancer, HPV (Source: MedlinePlus Health News)